drugset / Trial / NCT04052204
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Phase 1/2
Terminated
3 enrolled
Pfizer
Astellas Pharma Inc · collabEMD Serono · collabNektar Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant prostate cancer (mCRPC).
Timeline
- Start
- 2019-12-30
- Primary completion
- 2020-09-29
- Completion
- 2020-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Bempegaldesleukin | Protein / enzyme biologic | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |
| Subject | Talazoparib | Small molecule | — | — |